File Download

There are no files associated with this item.

  Links for fulltext
     (May Require Subscription)
Supplementary

Article: Neratinib after trastuzumab-based adjuvant therapy in patients from Asia with early stage HER2-positive breast cancer

TitleNeratinib after trastuzumab-based adjuvant therapy in patients from Asia with early stage HER2-positive breast cancer
Authors
KeywordsAsia
early stage breast cancer
efficacy
extended adjuvant therapy
HER2
Issue Date2019
PublisherFuture Medicine Ltd. The Journal's web site is located at http://www.futuremedicine.com/loi/fon
Citation
Future Oncology, 2019, v. 15 n. 21, p. 2489-2501 How to Cite?
AbstractAim: To evaluate the efficacy and safety of neratinib as extended adjuvant therapy in patients from Asia based on exploratory analyses of the Phase III ExteNET trial. Patients & methods: A total of 2840 women with early stage HER2-positive breast cancer were randomly assigned to neratinib 240 mg/day or placebo for 1 year after trastuzumab-based adjuvant therapy. Results: A total of 341 patients were from Asia (neratinib, n = 165; placebo, n = 176). 2-year invasive disease-free survival rates were 92.8 and 90.8% with neratinib and placebo, respectively (HR: 0.70; 95% CI: 0.31-1.55), and 5-year rates were 91.9 and 87.2%, respectively (HR: 0.57; 95% CI: 0.27-1.13). Diarrhea was the most common adverse event with neratinib. Conclusion: Extended adjuvant therapy with neratinib reduces disease recurrences in Asian women with HER2-positive breast cancer. Trial registration: Clinicaltrials.gov NCT00878709. © 2019 Future Medicine Ltd.
Persistent Identifierhttp://hdl.handle.net/10722/273926
ISSN
2017 Impact Factor: 2.369
2015 SCImago Journal Rankings: 0.957
ISI Accession Number ID

 

DC FieldValueLanguage
dc.contributor.authorIwata, H-
dc.contributor.authorMasuda, N-
dc.contributor.authorKim, SB-
dc.contributor.authorInoue, KSL-
dc.contributor.authorRai, YS-
dc.contributor.authorFujita, T-
dc.contributor.authorChiu, WYJ-
dc.contributor.authorOhtani, S-
dc.contributor.authorTakahashi, M-
dc.contributor.authorMiyaki, TY-
dc.contributor.authorLu, YS-
dc.contributor.authorXu, B-
dc.contributor.authorYap, YS-
dc.contributor.authorBustam, A-
dc.contributor.authorYao, B-
dc.contributor.authorZhang, B-
dc.contributor.authorBryce, R-
dc.contributor.authorChan, A-
dc.date.accessioned2019-08-18T14:51:28Z-
dc.date.available2019-08-18T14:51:28Z-
dc.date.issued2019-
dc.identifier.citationFuture Oncology, 2019, v. 15 n. 21, p. 2489-2501-
dc.identifier.issn1479-6694-
dc.identifier.urihttp://hdl.handle.net/10722/273926-
dc.description.abstractAim: To evaluate the efficacy and safety of neratinib as extended adjuvant therapy in patients from Asia based on exploratory analyses of the Phase III ExteNET trial. Patients & methods: A total of 2840 women with early stage HER2-positive breast cancer were randomly assigned to neratinib 240 mg/day or placebo for 1 year after trastuzumab-based adjuvant therapy. Results: A total of 341 patients were from Asia (neratinib, n = 165; placebo, n = 176). 2-year invasive disease-free survival rates were 92.8 and 90.8% with neratinib and placebo, respectively (HR: 0.70; 95% CI: 0.31-1.55), and 5-year rates were 91.9 and 87.2%, respectively (HR: 0.57; 95% CI: 0.27-1.13). Diarrhea was the most common adverse event with neratinib. Conclusion: Extended adjuvant therapy with neratinib reduces disease recurrences in Asian women with HER2-positive breast cancer. Trial registration: Clinicaltrials.gov NCT00878709. © 2019 Future Medicine Ltd.-
dc.languageeng-
dc.publisherFuture Medicine Ltd. The Journal's web site is located at http://www.futuremedicine.com/loi/fon-
dc.relation.ispartofFuture Oncology-
dc.subjectAsia-
dc.subjectearly stage breast cancer-
dc.subjectefficacy-
dc.subjectextended adjuvant therapy-
dc.subjectHER2-
dc.titleNeratinib after trastuzumab-based adjuvant therapy in patients from Asia with early stage HER2-positive breast cancer-
dc.typeArticle-
dc.identifier.emailChiu, WYJ: jwychiu@hku.hk-
dc.identifier.authorityChiu, WYJ=rp01917-
dc.description.naturelink_to_subscribed_fulltext-
dc.identifier.doi10.2217/fon-2019-0143-
dc.identifier.pmid31140297-
dc.identifier.scopuseid_2-s2.0-85070360441-
dc.identifier.hkuros301145-
dc.identifier.volume15-
dc.identifier.issue21-
dc.identifier.spage2489-
dc.identifier.epage2501-
dc.identifier.isiWOS:000482270600007-
dc.publisher.placeUnited Kingdom-

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats